Summary:
- AnaCardio has secured €62.5 million in Series B financing to accelerate the clinical development of AC01, a novel oral therapeutic candidate for patients with chronic heart failure.
- The funding will specifically support the advancement of the drug toward Phase 3 readiness, focusing on its unique mechanism of action as a positive inotrope that improves cardiac contractility without increasing oxygen demand.